Follow
Rona Yaeger
Rona Yaeger
Verified email at mskcc.org
Title
Cited by
Cited by
Year
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
RM Samstein, CH Lee, AN Shoushtari, MD Hellmann, R Shen, ...
Nature genetics 51 (2), 202-206, 2019
30342019
Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients
A Zehir, R Benayed, RH Shah, A Syed, S Middha, HR Kim, P Srinivasan, ...
Nature medicine 23 (6), 703-713, 2017
28922017
Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer
S Misale, R Yaeger, S Hobor, E Scala, M Janakiraman, D Liska, E Valtorta, ...
Nature 486 (7404), 532-536, 2012
20092012
OncoKB: a precision oncology knowledge base
D Chakravarty, J Gao, S Phillips, R Kundra, H Zhang, J Wang, ...
JCO precision oncology 1, 1-16, 2017
18982017
Encorafenib, Binimetinib, and Cetuximab in BRAF V600E–Mutated Colorectal Cancer
S Kopetz, A Grothey, R Yaeger, E Van Cutsem, J Desai, T Yoshino, ...
New England Journal of Medicine 381 (17), 1632-1643, 2019
11972019
PD-1 blockade in mismatch repair–deficient, locally advanced rectal cancer
A Cercek, M Lumish, J Sinopoli, J Weiss, J Shia, M Lamendola-Essel, ...
New England Journal of Medicine 386 (25), 2363-2376, 2022
7332022
Clinical sequencing defines the genomic landscape of metastatic colorectal cancer
R Yaeger, WK Chatila, MD Lipsyc, JF Hechtman, A Cercek, ...
Cancer cell 33 (1), 125-136. e3, 2018
6712018
Combined BRAF, EGFR, and MEK Inhibition in Patients with BRAFV600E-Mutant Colorectal Cancer
RB Corcoran, T André, CE Atreya, JHM Schellens, T Yoshino, JC Bendell, ...
Cancer discovery 8 (4), 428-443, 2018
5432018
Adoption of total neoadjuvant therapy for locally advanced rectal cancer
A Cercek, CSD Roxburgh, P Strombom, JJ Smith, LKF Temple, GM Nash, ...
JAMA oncology 4 (6), e180071-e180071, 2018
4882018
Microsatellite instability is associated with the presence of Lynch syndrome pan-cancer
A Latham, P Srinivasan, Y Kemel, J Shia, C Bandlamudi, D Mandelker, ...
Journal of clinical oncology 37 (4), 286, 2019
4852019
Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS
Z Yao, R Yaeger, VS Rodrik-Outmezguine, A Tao, NM Torres, MT Chang, ...
Nature 548 (7666), 234-238, 2017
4542017
Assessment of a watch-and-wait strategy for rectal cancer in patients with a complete response after neoadjuvant therapy
JJ Smith, P Strombom, OS Chow, CS Roxburgh, P Lynn, A Eaton, ...
JAMA oncology 5 (4), e185896-e185896, 2019
4322019
Comparative sequencing analysis reveals high genomic concordance between matched primary and metastatic colorectal cancer lesions
AR Brannon, E Vakiani, BE Sylvester, SN Scott, G McDermott, RH Shah, ...
Genome biology 15, 1-10, 2014
3612014
A rectal cancer organoid platform to study individual responses to chemoradiation
K Ganesh, C Wu, KP O’Rourke, BC Szeglin, Y Zheng, CEG Sauvé, ...
Nature medicine 25 (10), 1607-1614, 2019
3602019
Organ preservation in patients with rectal adenocarcinoma treated with total neoadjuvant therapy
J Garcia-Aguilar, S Patil, MJ Gollub, JK Kim, JB Yuval, HM Thompson, ...
Journal of clinical oncology 40 (23), 2546, 2022
3592022
Loss of NF1 in cutaneous melanoma is associated with RAS activation and MEK dependence
MH Nissan, CA Pratilas, AM Jones, R Ramirez, H Won, C Liu, S Tiwari, ...
Cancer research 74 (8), 2340-2350, 2014
3472014
Targeting alterations in the RAF–MEK pathway
R Yaeger, RB Corcoran
Cancer discovery 9 (3), 329-341, 2019
3372019
Encorafenib plus cetuximab as a new standard of care for previously treated BRAF V600E–mutant metastatic colorectal cancer: updated survival results and subgroup analyses from …
J Tabernero, A Grothey, E Van Cutsem, R Yaeger, H Wasan, T Yoshino, ...
Journal of Clinical Oncology 39 (4), 273, 2021
3142021
Pilot Trial of Combined BRAF and EGFR Inhibition in BRAF-Mutant Metastatic Colorectal Cancer Patients
R Yaeger, A Cercek, EM O'Reilly, DL Reidy, N Kemeny, T Wolinsky, ...
Clinical cancer research 21 (6), 1313-1320, 2015
2882015
TAS-120 overcomes resistance to ATP-competitive FGFR inhibitors in patients with FGFR2 fusion–positive intrahepatic cholangiocarcinoma
L Goyal, L Shi, LY Liu, F Fece de la Cruz, JK Lennerz, S Raghavan, ...
Cancer discovery 9 (8), 1064-1079, 2019
2742019
The system can't perform the operation now. Try again later.
Articles 1–20